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Abstract
Background: Severe asthma exerts a disproportionately heavy burden on patients and health care. Due to the
heterogeneity of the severe asthma population, many patients need to be evaluated to understand the clinical
features and outcomes of severe asthma in order to facilitate personalised and targeted care. The International
Severe Asthma Registry (ISAR) is a multi-country registry project initiated to aid in this endeavour.
Methods: ISAR is a multi-disciplinary initiative benefitting from the combined experience of the ISAR Steering
Committee (ISC; comprising 47 clinicians and researchers across 29 countries, who have a special interest and/or
experience in severe asthma management or establishment and maintenance of severe asthma registries) in
collaboration with scientists and experts in database management and communication. Patients (≥18 years old)
receiving treatment according to the 2018 definitions of the Global Initiative for Asthma (GINA) Step 5 or
uncontrolled on GINA Step 4 treatment will be included. Data will be collected on a core set of 95 variables
identified using the Delphi method. Participating registries will agree to provide access to and share standardised
anonymous patient-level data with ISAR. ISAR is a registered data source on the European Network of Centres for
Pharmacoepidemiology and Pharmacovigilance. ISAR’s collaborators include Optimum Patient Care, the Respiratory
Effectiveness Group (REG) and AstraZeneca. ISAR is overseen by the ISC, REG, the Anonymised Data Ethics &
Protocol Transparency Committee and the ISAR operational committee, ensuring the conduct of ethical, clinically
relevant research that brings value to all key stakeholders.
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Conclusions: ISAR aims to offer a rich source of real-life data for scientific research to understand and improve
disease burden, treatment patterns and patient outcomes in severe asthma. Furthermore, the registry will provide
an international platform for research collaboration in respiratory medicine, with the overarching aim of improving
primary and secondary care of adults with severe asthma globally.
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Background
Treatment of severe asthma is challenging because of the
heterogeneous nature of the disease, which comprises vari-
ous phenotypes and endotypes [1–3]. The heterogeneity of
airway inflammation in patients with severe asthma makes
profiling of patients considerably important toward identi-
fying “treatable traits” [4]. Moreover, while severe asthma
affects approximately 5% − 15% of all patients with asthma
[5–7], the associated impact on the lives of patients and
caregivers is disproportionately high [8, 9]. Inadequately
controlled severe asthma is also associated with poor clin-
ical outcomes and a high economic burden [9–12].
National and local asthma registries are a source of real-
world data for asthma management and may contain data at
the patient, provider and clinic levels [13–17]. However, be-
cause of considerable differences in the definitions of severe
asthma [5, 18–20] and country- and region-specific differ-
ences in access to health care [21, 22], patient populations in-
cluded in these registries may be heterogeneous in terms of
demographics, clinical characteristics, inflammatory pheno-
types, captured data and reported outcomes. Additionally,
depending on the size of existing asthma registries, they may
be limited by inadequate statistical power. As a result of this
heterogeneity, interpretation of data across patient popula-
tions and geographies can be challenging. Therefore, a stan-
dardised global dataset is urgently needed to:
 retain all the values of local registries and connect
them to enable and promote inter-operability, data
sharing and cross-comparison;
 have sufficient statistical power to answer pertinent
clinical and research questions;
 reduce the variability of data collected by
standardising variables across countries and regions;
 have pre-defined and extensive processes in place to
ensure that data capture and data harmonisation are
of high quality;
 improve understanding of the severe asthma
population and examine the response to therapies
and other interventions as a function of nationality,
phenotypes, biomarkers, current treatment and
socio-economic status; and
 permit continued development with long-term pa-
tient follow-up to enable a real-life understanding of
severe asthma.
The International Severe Asthma Registry (ISAR) is a
collaborative initiative comprising existing and new
registries that builds on data from multiple nations and
regions and increases the statistical power and compar-
ability of data. It is the first global adult severe asthma
registry to be established. The primary objectives of
ISAR (Fig. 1) are to describe and characterise the natural
history of the severe asthma patient population overall
and by different subgroups and to facilitate phenotyping
and endotyping of patients with severe asthma such that
these patient groups can be described by burden of ill-
ness, disease management patterns and clinical evolution
in an international setting. These objectives were devel-
oped to improve understanding of the clinical features
and outcomes of severe asthma, with the overarching
aim of improving the care of adults with severe asthma
globally.
Here, we describe the ISAR protocol for registry devel-
opment and management, the rationale behind each step
of the process and the potential benefits of ISAR to adult
patients with severe asthma.
Methods
Registry design and governance
ISAR, a multi-country, observational initiative, will both
prospectively and retrospectively collect data on adult
patients with severe asthma. A registered data source on
the European Network of Centres for Pharmacoepide-
miology and Pharmacovigilance (ENCePP) [23], ISAR is
currently supported by three core collaborators:
Optimum Patient Care (OPC), the Respiratory Effective-
ness Group (REG) and AstraZeneca. OPC is a not-for-
profit social enterprise providing medical research and
services to improve the diagnosis, treatment and care of
chronic diseases [24] and is responsible for ISAR data-
base management, data processing and analyses. REG is
an investigator-led, not-for-profit research initiative pro-
moting the value of real-life research [25]. AstraZeneca
and OPC are co-founders and joint sponsors of ISAR.
Oversight
ISAR is overseen by four governing bodies (Fig. 2): the
ISAR Steering Committee (ISC), REG, the Anonymised
Data Ethics & Protocol Transparency (ADEPT) Com-
mittee [26] and the ISAR Operational Committee.
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Fig. 1 Objectives of the International Severe Asthma Registry
Fig. 2 International Severe Asthma Registry governance. ADEPT Anonymised Data Ethics & Protocol Transparency, AZ AstraZeneca, ISAR
International Severe Asthma Registry, REG Respiratory Effectiveness Group
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The ISC comprises 47 clinicians and researchers
across 29 countries in North America, South America,
Europe, Asia, Middle East and Oceania, with a special
interest in severe asthma and/or experience in establish-
ing and maintaining a severe asthma registry. The ISC
also includes members of OPC and medical experts from
AstraZeneca. Since ISAR is an open registry, academic
and commercial entities can register their interest to
participate in ISAR and seek access to the data for re-
search purposes, with all research proposals requiring
approval by the ISC via a democratic voting process.
Each member country and AstraZeneca have one vote
on project selection, with OPC holding the casting vote
in the event of ties. AstraZeneca does not vote on re-
search proposals from commercial entities.
REG is the academic partner comprising over 420 ex-
perts in severe asthma and will provide academic over-
sight and support. The ADEPT Committee
(commissioned independently by REG), using pre-
specified criteria [24], will review and approve the scien-
tific merit of all research proposals submitted to ensure
scientific integrity, robustness and compliance with all
relevant ethical considerations and to ensure that the
database research is clinically appropriate and valuable
to patients, public health and health care.
The ISAR Operational Committee includes participat-
ing country representatives (e.g. country lead, deputy
and data managers) and will be involved in the day-to-
day running of ISAR. The Operational Committee
within each country is led by the country-specific ISC
member; therefore, sound procurement of data is also
partly ensured by the ISC.
Registries, countries and experts
Existing registries were selected for possible collabor-
ation via a systematic internet search of PubMed, MED-
LINE, EMBASE, Google Scholar and Web of Science
using broad search terms to identify all severe asthma
registries. Registries for participation in ISAR were iden-
tified with the help of REG’s and OPC’s global network
of leading respiratory scientists and severe asthma ex-
perts. These experts were either the lead of an existing
registry, were linked with the lead or had previously
expressed an interest in developing a severe asthma
registry for their respective country. Leaders of existing
and potential new severe asthma registries were
approached and formally invited by ISAR to discuss col-
laboration and contribution to the ISAR initiative.
Table 1 lists the existing and new registries collaborating
with ISAR.
To facilitate global collaboration efforts, various as-
pects of the ISAR structure and deliverables, such as
principles of data collection and sharing, as well as re-
search prioritisation, will be jointly discussed between
OPC and the lead entity for each registry/country and
will be tailored towards each contributing country dur-
ing the ISC meetings as well as country-specific meet-
ings. The lead entity, depending on the local
circumstances, could either be a university, a lead study
site or the respective national thoracic society. In all in-
stances, the lead entity is responsible for overseeing data
collection, including combining data from any satellite
sites, before making the country-wide data available to
ISAR. In countries with no existing registries, this ap-
proach, in effect, creates a country-level registry that al-
lows for the creation of a locally hosted central registry
for the country’s combined data, which can be used to
enhance local-level research, and provides longitudinal
data that will help clinicians and patients better under-
stand underlying phenotypes of severe asthma and en-
hance precision medicine.
The ethics application process differs among collabor-
ating registries. Within some registries, ethics approval
is required at each individual satellite site, whereas for
other collaborators, a central ethics committee can
process applications on behalf of all satellite sites.
In addition, the ISAR study group comprises core
panel members of ISAR who will provide collective ex-
pertise, scientific knowledge and experience in database
management and research (Additional file 1: Appendix).
Patients
Patients in ISAR will be included from the participating
existing and newly created local/regional registries. To
be included, patients (≥18 years of age) should be receiv-
ing treatment according to the 2018 definitions of the
Global Initiative for Asthma (GINA) Step 5 or should be
uncontrolled on GINA Step 4 treatment [19, 27]. Un-
controlled asthma is defined as per the American Thor-
acic Society/European Respiratory Society criteria [5].
Detailed inclusion and exclusion criteria are listed in
Table 2. These eligibility criteria were chosen to reflect
severe asthma patients in the real-world setting and to
broaden the scope to include patients with uncontrolled
moderate-to-severe asthma. Notably, patients with a his-
tory of smoking are not excluded. In addition, patients
with asthma-chronic obstructive pulmonary disease
overlap (ACO), as defined in the 2018 GINA report [19],
will be included. Informed consent will be obtained from
patients where required to allow anonymised data shar-
ing for approved research projects.
On average, 2000 new patients will be enrolled globally
each year, for at least 5 years from the start of ISAR
(May 2017). Patients receiving care at severe asthma sec-
ondary and tertiary care centres in each participating
country will be included, in accordance with local regu-
latory/ethics requirements. One follow-up per year is re-
quired with collaborating centres, which is in line with
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the minimum number of visits to a severe asthma spe-
cialist centre expected per patient. A minimum of two-
thirds of patients enrolled within each participating
registry are predicted to be retained for annual follow-
up, after adjusting for attrition.
Database
The ISAR initiative is a partnership with national and re-
gional registries, such that each participating registry re-
tains ownership of their own data, but shares their
anonymised and de-identified data with ISAR for ap-
proved research purposes.
A collaboration and data sharing agreement will be ne-
gotiated and signed between OPC and the lead entity of
each registry. The agreement will govern the:
 method of storage and transmission of data;
 data security and compliance with OPC data
security standards;
 list of variables required to be extracted from each
country-specific database;
Table 1 List of existing and new registries collaborating with ISAR
Registry status Collaborating country Registry name Start year
Existing Registry UK UK Severe Asthma Registry 2006
USA National Jewish Health Electronic Medical Record (NJH EMR) 2010
South Korea Severe Asthma Work Group of Korean Academy of Asthma,
Allergy and Clinical Immunology (KAAACI)
2010
Germany German Asthma Network (GAN) 2011
Australia & New Zealand Australasian Severe Asthma Registry (ASAR) hosted by TSANZ 2013
Ireland INhaler Compliance Assessment in Severe Unstable Asthma (INCA SUN) 2015
Italy Severe Asthma Network Italy (SANI) 2016
Spain Spanish Guideline on the Management of Asthma Database (GEMA-Data) 2017
New Registry Denmark Danish Severe Asthma Registry (DSAR) 2018
Sweden Swedish Severe Asthma Registry Starting in 2020
Finland Currently collecting data independently from ISAR 2019
Iceland Currently collecting data independently from ISAR 2020
Norway Starting in 2021
Bulgaria Bulgarian Severe Asthma Registry (BULSAR) 2018
Portugal Portugal Severe Asthma Registry (Registo de Asma Grave Portugal [RAG]) 2018
Russia Russian Severe Asthma Registry (RSAR) 2018
Argentina Argentinian Severe Asthma Registry 2019
Belgium Currently collecting data independently from ISAR 2018
Brazil Brazilian Severe Asthma Registry Starting in 2020
Canada Canadian Severe Asthma Registry 2019
China Starting in 2021
Colombia Colombian Severe Asthma Registry 2019
France French Severe Asthma Registry 2019
Greece Greek Severe Asthma Registry 2019
India Indian Severe Asthma Registry 2019
Japan Japanese Severe Asthma Registry 2019
Kuwait Kuwaitian Severe Asthma Registry 2018
Mexico Mexican Severe Asthma Registry 2019
Poland Polish Severe Asthma Registry 2020
Saudi Arabia Saudi Arabian Severe Asthma Registry 2019
Singapore Singapore Severe Asthma Registry (S-SAR) 2020
Taiwan Taiwanese Severe Asthma Registry 2019
UAE UAE Severe Asthma Registry 2019
ISAR International Severe Asthma Registry, UAE United Arab Emirates, UK United Kingdom, USA United States of America
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 oversight (by OPC) to ensure confidentiality of the
data received; and
 remote retrieval and appraisal of data from each
country by OPC.
The steps involved in data acquisition, quality control
and management of ISAR have been outlined in Fig. 3.
Data collection
Data will be collected from a combination of existing
and new registries, and each country will have a data
collector trained in human subject research with relevant
experience in Good Clinical Practice or country-specific
equivalent guidelines. A small and limited financial in-
centive is also provided to compensate for any time
Table 2 ISAR patient inclusion and exclusion criteria
Inclusion Exclusion
Adult (≥18 years old) patients with severe asthma Lack of informed consent for participation
Undergoing GINA Step 5 treatmenta [19] or
Uncontrolled on GINA Step 4 treatment [19]
Uncontrolled defined as at least one of the following (per ATS/ERS guidelines [5]):
Poor symptom control: ACQ consistently > 1.5, ACT < 20 (or ‘not well controlled’) [19]
Airflow limitation: Pre-bronchodilator FEV1 < 80% predicted, with reduced FEV1/FVC
(defined as less than the lower limit of normal)
Serious exacerbations: ≥1 hospitalisation, ICU stay or mechanical ventilation in the previous year
Frequent severe exacerbations: ≥2 bursts of systemic corticosteroids with each course > 3 days
in the previous year
aAsthma controlled on high-dose ICS/LABA treatment was not part of the current inclusion for ISAR as this treatment approach is not yet adopted by clinicians
ACQ Asthma Control Questionnaire, ACT Asthma Control Test, ATS American Thoracic Society, ERS European Respiratory Society, FEV1 forced expiratory volume in
1 s, FVC forced vital capacity, GINA Global Initiative for Asthma, ICS inhaled corticosteroids; ICU intensive care unit, ISAR International Severe Asthma Registry, LABA
long-acting β2-agonist
Fig. 3 Steps involved in data collection, transfer and storage. eCRF electronic case report form, EDC electronic data capture, ISAR International
Severe Asthma Registry, OPC Optimum Patient Care
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spent on data entry by health care providers or allied
workers. To accommodate the recently enacted Euro-
pean Union General Data Protection Regulation (EU
GDPR) [28], and/or local ethics regulatory mandates,
some countries will provide summarised statistics for re-
search projects, while others will provide individual-level
data in the initial stage of the ISAR collaboration. How-
ever, all registries (as required) plan and work with eth-
ics committees to transfer individual-level data. ISAR
will collect only anonymised data from all collaborating
registries and ensure that the strictest security measures
are in place for data sharing and hosting. A data transfer
standard operating procedure (SOP) is provided to each
registry to guide the anonymous and safe transfer of
data.
Data from the existing registries will be collected using
existing systems (e.g. Dendrite Clinical Systems, United
Kingdom [UK]; REDCap, Australia; Zitelab, Denmark)
that are largely aligned with the standard data collection
fields of ISAR. Data imported will be as per instructions
listed in a separate ISAR data management plan, which
will be provided to all registries. Data will be collected
using a comprehensive electronic case report form
(eCRF; screenshot in Fig. 4). Although registries can
enter data directly in the eCRFs, they can also opt to col-
lect the data on paper and enter it into the eCRF later,
based on their clinical process. All eCRFs will be com-
pleted by designated personnel trained (via an on-site/
remote training session) on data entry, and a data collec-
tion SOP will be provided with instructions on how to
complete the CRF/eCRF, with a detailed explanation of
the data fields. Data collection will comply with the stan-
dards established by the ISC and agreed by each partici-
pating registry, allowing datasets across all registries to
be combined. These procedures are set in place to en-
sure uniform interpretation of variables across countries
and cultures, further effectively standardising ISAR data.
Data quality and management
Functions, processes and specifications for data collec-
tion, extraction, delivery and cleaning are outlined in the
ISAR data management plan. For instance, data quality
is ensured before and during the data collection process
through a series of pre-programmed data quality checks
Fig. 4 International Severe Asthma Registry electronic case report form (screenshot). ATS American Thoracic Society, ERS European Respiratory
Society, FEV1 forced expiratory volume in 1 second, FVC forced vital capacity, NAEPP National Asthma Education and Prevention Program
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that automatically detect out-of-range or anomalous en-
tries on the eCRF. Most of the fields requested on the
ISAR eCRF are numeric or categorical to minimise data
entry errors. After data extraction, further data cleaning
and validation processes will also be performed on all
data to maximise data quality control. Ad hoc queries,
done at the country level or OPC level, will be generated
within the electronic data capture (EDC) system and
followed up with country data managers and/or the
country study coordinator (where applicable) for reso-
lution. All data modifications will be recorded in an
audit log and all data transfers and disputes will be
shared and documented in the country and ISAR central
data manager logs.
Electronic data capture
All new data will be entered directly into the EDC sys-
tem (REDCap or OpenClinica). Where feasible, patient
data from electronic medical records will be integrated
with the EDC systems to maximise data collection re-
sources and reduce the time needed for data entry. Both
new and existing data collection platforms will accom-
modate ISAR variables and anonymise and de-identify
data prior to importing it to the central data warehouse,
where the data will be stored with a unique patient iden-
tification number. The key code linking the unique iden-
tifier to the relevant patient will be held by the patient’s
health care provider. ISAR will have no access to the
linkage files. All participating sites will have access to
their own data and will be trained on using the available
online data capture systems. Physician and data entry
personnel will be able to access their local EDC account
with a username and password, with each user being
prompted to change their unique password on a yearly
basis.
OPC will be responsible for monitoring and mapping
the data into the central ISAR data repository by using
the Systematized Nomenclature of Medicine Clinical
Terms (SNOMED CT) code [29] for standardised use
globally. In addition, all existing registries using unique
EDC systems will be responsible for extracting batches
of patient data at a quarterly frequency for inclusion to
ISAR. OPC will be responsible for safely transporting
and importing each batch into the central ISAR data re-
pository permitted by specific country’s data regulations.
For countries with data sharing regulations delimiting
data privacy, such as the EU GDPR, ISAR will accom-
modate anonymised data sharing on a project-by-project
basis. In these cases, the patient-level data are kept/
hosted within the country and shared as needed for ap-
proved ISAR research.
Registry variables
A modified Delphi consensus–driven approach [30] was
used to develop a standardised set of core and research
variables for ISAR [31]. The ISC will hold regular meet-
ings to ensure continued expert input throughout the
development and expansion of the registry, in terms of
the collaborators and investigators added, as well as data
collected. Standardised data will be collected in three
distinct fields:
Core variables These comprise 13 categories encom-
passing 95 core variables (Fig. 5; Additional file 2: Table
S1), which include data on patient demographics, med-
ical history and diagnostics, clinical characteristics,
patient-reported outcomes and treatment management
plans. These core variables are mandatory and should be
collected by any registry wishing to contribute data to
ISAR. Additional variables (e.g. those collected by the
UK registry) can be reviewed by each ISAR member and
included into the core variable list. However, no change
is planned in the core variables for the first 5 years of
ISAR. Each country is permitted to keep any number of
Fig. 5 International Severe Asthma Registry variables. aCollected by all participating registries. GINA Global Initiative for Asthma
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these additional variables as extended variables in their
own local registry/database.
Safety and effectiveness bolt-on variables Safety vari-
ables (Fig. 5; Additional file 3: Table S2) comprising se-
vere infections, malignancy and anaphylactic reactions
were chosen because of evidence indicating the potential
association between the use of biologics and these ad-
verse events [32, 33]. Considering that these outcomes
and associations have mostly been studied in small pop-
ulations, the inclusion of these safety bolt-on variables
will enable investigation and evaluation of these in a lar-
ger, global population with severe asthma.
Similarly, the effectiveness variables (Fig. 5; Additional
file 3: Table S2) were selected to collect indications of
osteoporosis, circulatory system diseases, ocular diseases
(glaucoma and cataract), renal failure, type II diabetes
mellitus, depression, anxiety, pneumonia, peptic ulcer,
obstructive sleep apnoea and details on oral and inhaled
corticosteroid doses, as well as reasons for medication
therapy switches.
Additional research variables These comprise all vari-
ables deemed useful for scientific research and maximal
data collection, such as occupation, medical history, add-
itional comorbidities, diagnostics, spirometry variables,
biomarkers, asthma control, quality of life or depression
and anxiety questionnaire, other asthma medications
and paediatric severe asthma (Fig. 5; Additional file 4:
Table S3). Extended variables will be collected via stan-
dardised bolt-on modules and will be available by choice
to registries according to their preference. If resources
allow, each registry is free to add additional variables of
specific local interest, such as pregnancy, to their data
collection tool.
Data ownership
Each country retains ownership of their data, and all
participating countries agree to allow output of data
from their respective registries upon joining ISAR for
collaborative independent research approved by the ISC
and ADEPT. The extraction and integration of datasets
for ethically approved research studies will be managed
by OPC, and the nature and frequency of data extraction
and transfer (quarterly) from registries to OPC are de-
tailed in the ISAR data sharing agreement.
Research
In terms of research output, the interim research goal of
ISAR is to complete one global research project per year
and to create four additional project-specific datasets for
academic and commercial research by ISAR members.
Non-core research activities will be presented as an
additional two abstracts and two manuscripts per year
from 2018 to 2021.
While ISAR will continue to actively seek out new
partners, new collaborators may also join ISAR by using
the ‘Join Us or Register Interest’ option on the ISAR
home page (http://isaregistries.org/). Research ideas may
be suggested by ISC members, country leads, and con-
tributors and visitors to the ISAR website (which may
include third party commercial and academic research
organisations), by clicking the ‘Submit Proposal or Re-
quest Research’ tab on the ISAR home page. All research
ideas will be reviewed, assessed and prioritised by the
ISC. Notably, regardless of commercial partners or col-
laborators, there will be no inferential drug-to-drug
comparison in ISAR; however, in the context of baseline
patient characteristics and treatment patterns (e.g.
switching), the proportions of patients on specific bio-
logics may be described and comparisons of outcomes
may be made between different biologics by class.
ISAR is open to other datasets that are not part of the
core ISAR projects but have alignment of variables,
which will enable combining data for specific projects.
Thus, combining and collaborating with other databases
or extracting data from other databases for specific pro-
jects is an available option.
Discussion
ISAR is a global collaborative initiative that allows for
prospectively and retrospectively analysing real-life se-
vere asthma data at the patient-level. It is conducted by
OPC, with academic and regulatory oversight from the
ISC, academic support from REG, ethical governance
from ADEPT and joint funding support from OPC and
AstraZeneca. ISAR is facilitated by standard data collec-
tion via a core set of variables across all participating
registries and supporting data collection via electronic
data capture, hosting and data entry. Benefitting from
the use of aggregate vs. individualised data, ISAR is large
enough to provide sufficient statistical power to detect
differences and trends. It thus enables collaborating
registries to answer key research questions on asthma at
a global scale.
Currently, ISAR’s membership includes registries from
more than 30 participating countries (Fig. 6). The inclu-
sive nature of ISAR will allow for extensive collaboration
and potentially new research ideas. To ensure transpar-
ency, ISAR has in place a democratic voting system for
selection of core research projects. In addition, data
quality checks run by ISAR may lead to a robust dataset
enabling quality research if countries decide to conduct
their own research with their local data. Overall, ISAR
aims to consolidate current knowledge of severe asthma
based on six key strengths (Fig. 7), including its global
reach, high quality data drawn from a large sample size,
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organisational structure, experience with database man-
agement inclusivity and expertise, enabling the gener-
ation of research that can have an impact on patient
care globally.
Certain limitations of ISAR should be acknowledged.
First, any database is only as good as the data it contains
(i.e. what is measured, in whom, how and the extent of
missing data). Second, due to their design, registry data
may possess lower internal validity than data collected
prospectively in randomised clinical trials, limiting the
extent to which they can support causal relationships.
The large volume of data also creates the potential for
many analyses with selective reporting, although this will
be mitigated by open disclosure of the research con-
ducted on the dataset and the respective results. While
ISAR has a broad representation from a number of
countries, for some, there may be limited representation
within the country itself. For example, ISAR currently
covers only one site in the United States. Lastly, to be-
come a truly global representation of severe asthma,
Fig. 6 Current International Severe Asthma Registry snapshota. aSource: image created in-house. UAE United Arab Emirates, UK United Kingdom,
USA United States of America
Fig. 7 Key strengths of the International Severe Asthma Registry. ISAR International Severe Asthma Registry
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funding issues need to be overcome to include patients
from sub-Saharan Africa and other low-to-middle in-
come countries.
The ISAR initiative has already led to the generation
of key data in the severe asthma field. The research topic
prioritised by the ISC in the inaugural year 2017 was the
‘Demographic and clinical characteristics of severe asthma
patients worldwide’. Characteristics described included
demographic distribution, medication, comorbidities,
asthma control, blood eosinophil counts, immunoglobulin
E (IgE) levels, lung function and health care resource use.
In total, 4990 patients from five registries contributed to
this first research project of ISAR [34]. In 2018, the global
research project was on the characterisation and compari-
son of eosinophilic and non-eosinophilic phenotypes
(Manuscript under journal review). The primary objective
was to describe and compare the demographic and clinical
features of eosinophilic compared with non-eosinophilic
asthma phenotypes in an international cohort of adult pa-
tients with severe asthma. The broader definitions of type
2 vs. non-type 2 asthma [35] will also be examined. The
core project prioritised by the ISC for 2019 is the ‘Com-
parative effectiveness across severe asthma biologic classes
(anti-interleukin-5 vs. anti-IgE targeted therapy) in pa-
tients eligible for both modalities’. Furthermore, additional
ISAR research projects are prioritised and are open to re-
searchers to join and lead (Table 3). Overall, the clinical
questions that ISAR plans to answer are varied and range
from a description of the patient population to the
assessment of any differences between disease subtypes,
drivers of treatment switching, biomarker profiles and the
development of a protocol to identify hidden severe
asthma.
There is precedence for the use of global registries to
facilitate international collaboration and contribute to our
understanding of other diseases [36, 37]. For example, the
Translational Research in Europe – Assessment & Treat-
ment of Neuromuscular Diseases (TREAT-NMD), which
is a network for the neuromuscular field, enabled harmo-
nised implementation of registries featuring patients with
Duchenne’s muscular dystrophy [36]. The European
Register for Multiple Sclerosis (EUReMS) was created to
enable comparisons across EU countries by merging data
from existing national multiple sclerosis registries and re-
gional cohorts [37]. In rheumatology, collaboration across
global registries made access to rich data sources possible,
enabling investigation of safety outcomes among a geo-
graphically diverse rheumatoid arthritis patient popula-
tion [38]. Thus, ISAR has the potential to become an
important platform to facilitate severe asthma research.
Furthermore, the protocol described here can potentially
be used as a foundation in other diseases, where divergent
national and regional registries preclude collaboration
and inter-operability between registries.
In the future, ISAR plans to include additional coun-
tries, covering Africa, Asia, South America, the Middle
East and Eastern Europe. Other prospects include link-
ages with other databases and integration with electronic
Table 3 Prioritised research projects for 2018, 2019 and 2020
Project Investigator
2018
Biologics in severe asthma: utilisation patterns, causes for discontinuation and switching and
adverse outcomes
Professor Andrew Menzies-Gow (UK)
Hidden severe asthma patients in primary care vs. ISAR Professor David Price (Singapore)
Relationship between socioeconomic status and asthma outcomes Professor Liam Heaney (UK)
The impact of exacerbation burden on lung function trajectory in a broad asthma population
and severe asthma population
Professor Liam Heaney (UK)
Biomarker Relatability in the International Severe Asthma Registry (BRISAR) Dr. Eve Denton and Dr. Mark Hew (Australia)
Identification of predictors (i.e. biomarkers) of response to biologics Dr. Eve Denton and Dr. Mark Hew (Australia)
Hidden chronic asthma within the COPD/ACO population Professor Chin Kook Rhee (South Korea)
Age of onset of asthma in severe asthma patients Dr. Enrico Heffler (Italy)
2019
Describe the OCS landscape: annual consumption, prevalence, outcomes and side effects of long-term OCS users
Criteria for choosing and switching between similar biological treatment options in patients with atopic and non-atopic severe eosinophilic asthma
2020
What is the impact of co-morbidity in severe asthma?
Define responders and non-responders to biologics and describe their characteristics overall and per biologic
Describe the clinical outcome before and after biologic treatment by biologic class, by individual biologic, and by subgroups of baseline characteristics
ACO asthma-chronic obstructive pulmonary disease overlap, COPD chronic obstructive pulmonary disease, FEV1 forced expiratory volume in 1 second, ISAR
International Severe Asthma Registry, OCS oral corticosteroids, UK United Kingdom
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medical records. In addition, longitudinal research in pa-
tients with less severe asthma and the development of a
paediatric ISAR in order to cover the entire severe
asthma life cycle are also being considered.
Conclusion
ISAR is the first global registry for adult severe asthma
that captures a large volume of standardised, inter-
national data on severe asthma. By acting as a data cus-
todian of international patient data, ISAR works as an
open border initiative, providing a platform to facilitate
data sharing. The registry provides enough statistical
power to address important research questions in severe
asthma aimed at a wide range of topics, including know-
ledge of patient presentations, disease heterogeneity
and the natural history of severe asthma; diagnosis and
disease stratification; identification of predictors of treat-
ment success and new treatment targets; demonstration
of how treatments are used in real-life and how effective
they are; long-term safety in different patient popula-
tions and comparison of differences between countries
and care systems. Through ISAR, it is expected that the
harmonised, standardised nature of data contained and
the collaborative partnerships being made possible may
reveal previously unthought of or hitherto neglected re-
search avenues.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12874-020-01065-0.
Additional file 1: Appendix. International Severe Asthma Registry
study group.
Additional file 2: Table S1. Full list of ISAR 95 core variables.
Additional file 3: Table S2. International Severe Asthma Registry bolt-
on variables.
Additional file 4: Table S3. International Severe Asthma Registry
optional additional research variables.
Abbreviations
ACO: asthma-chronic obstructive pulmonary disease overlap; ACQ: Asthma
Control Questionnaire; ACT: Asthma Control Test; ADEPT: Anonymised Data
Ethics & Protocol Transparency; ATS: American Thoracic Society;
eCRF: Electronic Case Report Form; EDC: Electronic Data Capture;
ENCePP: European Network of Centres for Pharmacoepidemiology and
Pharmacovigilance; ERS: European Respiratory Society; EU GDPR: European
Union General Data Protection Regulation; EUReMS: European Register for
Multiple Sclerosis; FEV1: forced expiratory volume in 1 s; FVC: forced vital
capacity; GINA: Global Initiative for Asthma; ICS: inhaled corticosteroids;
ICU: intensive care unit; IgE: immunoglobulin E; ISAR: International Severe
Asthma Registry; ISC: ISAR Steering Committee; LABA: long-acting β2 agonist;
OPC: Optimum Patient Care; REG: Respiratory Effectiveness Group; SNOMED
CT: Systematized Nomenclature of Medicine Clinical Terms; SOP: standard
operating procedure; TREAT-NMD: Translational Research in Europe –
Assessment & Treatment of Neuromuscular Diseases; UK: United Kingdom
Acknowledgements
The authors thank the following individuals who contributed to the initial
set-up of ISAR, provided input to the development of the protocol and/or
were involved in local implementation of ISAR: Elisabeth Bel, Roland Buhl,
Sverre Lehmann, Stelios Loukidis, Richard Martin, Juno Pak, Pearlanne Zelar-
ney, Joy Zimmer, Christena Kolakowski, Margo Brown, Jessica Cummings,
Jennifer Brandorff, Seth Skelton, John Upham, Philip Bardin, Paul Reynolds,
David Langton, Peter Middleton, Belinda Cochrane, Katya Vasileva Noleva,
Plamen Hristov Yakovliev, Sonya Metodieva Genova, Violina Milchova Vasi-
leva, Darina Petrova Dimova, Nadezhda K Takovska, Cvetantka Hristova Odz-
hakova, Eleonora M Stamenova, Diana X Hristova, Vincente Plaza, Ian Hirsch,
Cekomir Vodenicharov, Alexandrina Vodenicharova and Magdalena
Alexandrova.
Medical writing support was provided by Michelle Rebello, PhD, and Liam
Gillies, PhD, of Cactus Communications (Mumbai, India).
Authors’ contributions
AHM-vdZ, AA, AM-G, AB, BGC, CAP, CKR, CMP, DBP, DJJ, DL, EH, EW, GB, GC,
GWC, JB, JMF, IC, JZ, LB1, LB2, LGH, LL, LP, MA, MEW, MH, MP, MS, MSK, NE,
NH, NP, PEP, PG, RBM, RJ, RWC, TAP, TI, TL, TNT, UB, VB, VC, YSC and YT made
substantial contributions to conception and design of the protocol, took part
in drafting the article or revising it critically for important intellectual content,
gave final approval of the version to be published and agree to be account-
able for all aspects of the work.
Funding
The International Severe Asthma Registry is conducted by Optimum Patient
Care Global Limited, and co-funded by Optimum Patient Care Global Limited
and AstraZeneca. ISAR is supported by grants from AstraZeneca and Optimum
Patient Care (OPC) Global (a not-for-profit social enterprise). The ISAR steering
committee (ISC) was involved in the development of the protocol and is re-
sponsible for approving research proposals via a democratic voting process. In
addition to 47 clinicians and researchers with an interest and experience in se-
vere asthma, the ISC also includes members of OPC and four medical experts
from AstraZeneca. AstraZeneca reviewed the draft before submission; however,
decision to submit was made by the authors. Medical writing support was
funded by AstraZeneca in accordance with Good Publication Practice (GPP3)
guidelines (http://www.ismpp.org/gpp3).
Availability of data and materials
Not applicable.
Ethics approval and consent to participate
The ethics application process differs among participating registries/countries
in ISAR. Within some registries, ethics approval is required at each individual
satellite site, whereas for other collaborators, a central ethics committee can
process applications on behalf of all satellite sites.
Informed consent will be obtained from patients where required to allow




AHM-vdZ declares unrestricted grants from GlaxoSmithKline, Novartis and
Boehringer Ingelheim, personal fees for advisory board activities from
AstraZeneca and a travel grant from Chiesi. AA has received lecture fees
from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, MSD,
Norameda, Novartis and Orion; sponsorships from AstraZeneca, Boehringer
Ingelheim, Chiesi, GlaxoSmithKline, MSD, Norameda and Novartis; and has
been a member of advisory boards for AstraZeneca, Boehringer Ingelheim,
GlaxoSmithKline, Novartis and Teva. AM-G declares grants from AstraZeneca,
Boehringer Ingelheim, GlaxoSmithKline and Hoffman La Roche; consultancy
agreements with AstraZeneca, Sanofi and Vectura; attendance at advisory
boards for AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis,
Sanofi and Teva; received speaker fees from AstraZeneca, Boehringer Ingel-
heim, Novartis, Teva and Vectura; and attended international conferences for
Boehringer Ingelheim and Teva. AB has received speaker fees and grants to
his institution from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithK-
line and Novartis for unrelated projects. CMP, DL, GC, JB, JMF, MS, RBM, TAP,
TL, UB, VB and YSC have no relevant conflicts of interest. CKR declares con-
sultancy and lecture fees from AstraZeneca, Boehringer Ingelheim, GlaxoS-
mithKline, MSD, Mundipharma, Novartis, Sandoz, Takeda and Teva-Handok.
CAP, IC, LB2, NE, NH and VC are employees of Optimum Patient Care, a co-
funder of the International Severe Asthma Registry. DJJ has received advisory
FitzGerald et al. BMC Medical Research Methodology          (2020) 20:212 Page 12 of 14
board and speaker fees from AstraZeneca, GlaxoSmithKline, Boehringer Ingel-
heim, Teva, Napp Pharmaceuticals, Chiesi and Novartis and research grant
funding from AstraZeneca. DBP declares board membership with Aerocrine,
Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Mylan, Mundipharma,
Napp Pharmaceuticals, Novartis and Teva; consultancy agreements with
Almirall, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline,
Mylan, Mundipharma, Napp Pharmaceuticals, Novartis, Pfizer, Teva and Thera-
vance; grants and unrestricted funding for investigator-initiated studies (con-
ducted through Observational and Pragmatic Research Institute Pte Ltd)
from Aerocrine, AKL Research and Development Ltd., AstraZeneca, Boehrin-
ger Ingelheim, British Lung Foundation, Chiesi, Mylan, Mundipharma, Napp
Pharmaceuticals, Novartis, Pfizer, Respiratory Effectiveness Group, Teva, Thera-
vance, UK National Health Service and Zentiva; payment for lectures/speak-
ing engagements from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi,
Cipla, GlaxoSmithKline, Kyorin, Mylan, Merck, Mundipharma, Novartis, Pfizer,
Skyepharma and Teva; payment for manuscript preparation from Mundi-
pharma and Teva; payment for the development of educational materials
from Mundipharma and Novartis; payment for travel/accommodation/meet-
ing expenses from Aerocrine, AstraZeneca, Boehringer Ingelheim, Mundi-
pharma, Napp Pharmaceuticals, Novartis and Teva; funding for patient
enrolment or completion of research from Chiesi, Novartis, Teva and Zentiva;
stock/stock options from AKL Research and Development Ltd., which pro-
duces phytopharmaceuticals; owns 74% of the social enterprise Optimum Pa-
tient Care Ltd. (Australia and UK) and 74% of Observational and Pragmatic
Research Institute Pte Ltd. (Singapore); and is a peer reviewer for grant com-
mittees of the Efficacy and Mechanism Evaluation programme and Health
Technology Assessment. EH has been on advisory boards for Sanofi-
Genzyme, GlaxoSmithKline, Novartis, Circassia and Nestlè Purina. EW has re-
ceived advisory board fees from AstraZeneca. She has been an investigator
on clinical trials sponsored by AstraZeneca, GlaxoSmithKline, Novartis, Teva
and National Institute of Allergy and Infectious Diseases (NIAID), for which
her institution has received funding. BGC reports personal fees and non-
financial support from Novartis, grants and personal fees from AstraZeneca,
Chiesi and Menarini; personal fees and non-financial support from Teva,
grants from Boehringer Ingelheim and personal fees from Sanofi and Mundi-
pharma, outside the submitted work. GWC has received research grants as
well as lecture or advisory board fees from Menarini, Alk-Abello, Allergy Ther-
apeutics, Anallergo, AstraZeneca, MedImmune, Boehringer Ingelheim, Chiesi
Farmaceutici, Circassia, Danone, Faes, Genentech, Guidotti-Malesci, GlaxoS-
mithKline, Hal Allergy, Merck, MSD, Mundipharma, Novartis, Orion, Sanofi-
Aventis, Sanofi, Genzyme/Regeneron, Stallergenes, UCB Pharma, Uriach
Pharma, Teva, Thermo Fisher and Valeas. GB has received honoraria for lec-
tures from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline,
Novartis and Teva. He is a member of advisory boards for AstraZeneca, Boeh-
ringer Ingelheim, GlaxoSmithKline, Novartis, Sanofi/Regeneron and Teva. JZ,
MA and TNT are employees of AstraZeneca, a co-funder of the International
Severe Asthma Registry. LL declares personal fees for consultancy and lec-
tures from ALK, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline,
Mundipharma, Novartis, Orion Pharma, Sanofi and Teva. LB1 has (in the last
three years) received lecture or advisory board fees from Alk-Abello, AstraZe-
neca, Boehringer, Chiesi, GlaxoSmithKline, Mundipharma, Novartis, Sanofi,
Genzyme/Regeneron and Teva. LGH declares he has received grant funding,
participated in advisory boards and given lectures at meetings supported by
Amgen, AstraZeneca, Boehringer Ingelheim, Circassia, Hoffmann la Roche,
GlaxoSmithKline, Novartis and Teva; he has taken part in asthma clinical trials
sponsored by Boehringer Ingelheim, Hoffmann la Roche and GlaxoSmithK-
line, for which his institution received remuneration; and he is the Academic
Lead for the Medical Research Council Stratified Medicine UK Consortium in
Severe Asthma, which involves industrial partnerships with a number of
pharmaceutical companies, including Amgen, AstraZeneca, Boehringer Ingel-
heim, GlaxoSmithKline, Hoffmann la Roche and Janssen. LP declares non-
financial support, personal fees and grants from Teva; non-financial support
and personal fees from Boehringer Ingelheim, Esteve, GlaxoSmithKline, Mun-
dipharma and Novartis; personal fees and grants from AstraZeneca and
Chiesi; personal fees from Sanofi and non-financial support from Menarini,
outside the submitted work. MH declares grants and other advisory board
fees (made to his institutional employer) from AstraZeneca, GlaxoSmithKline,
Novartis and Seqirus for unrelated projects. MP declares personal fees and
non-financial support from AstraZeneca and GlaxoSmithKline. MEW reports
receiving consulting honoraria from AstraZeneca, Boehringer Ingelheim, Gen-
entech, GlaxoSmithKline, Novartis, Regeneron, Sanofi and Teva. MSK has been
a member of advisory boards for AstraZeneca, GlaxoSmithKline and Sanofi
and has received honoraria from AstraZeneca, GlaxoSmithKline and Sanofi.
NP declares speaker fees and grants to his institution from AstraZeneca, Glax-
oSmithKline and Novartis for unrelated projects. PEP declares speaker fees
and grants to his institution from AstraZeneca, GlaxoSmithKline and Novartis
for unrelated projects. PG declares speaker fees and grants to his institution
from AstraZeneca, GlaxoSmithKline and Novartis for unrelated projects. RWC
has received honoraria for lectures from Aerogen, AstraZeneca, Boehringer
Ingelheim, GlaxoSmithKline, Novartis and Teva. He is a member of advisory
boards for GlaxoSmithKline and Novartis, has received grant support from
GlaxoSmithKline and Aerogen and has patents in the use of acoustics in the
diagnosis of lung disease, assessment of adherence and prediction of exacer-
bations. RJ declares grants from Novartis, GlaxoSmithKline and AstraZeneca;
personal fees for consultancy and speaker fees or travel support from GlaxoS-
mithKline, AstraZeneca, Boehringer Ingelheim, Chiesi, Nutricia, OPRI and Pfi-
zer. TI declares grants from Astellas, Boehringer Ingelheim, Daiichi-Sankyo,
Kyorin, Meiji Seika Pharma and Teijin Pharma and lecture fees from Kyorin. YT
declares honoraria from Kyorin Pharma and Teijin Pharma and research fund-
ing from Kyorin and Meiji Seika Pharma.
Author details
1The Institute for Heart Lung Health, Vancouver, Canada. 2AstraZeneca,
Gaithersburg, USA. 3Department of Pulmonary Medicine, University of Tartu
and Lung Clinic, Tartu University Hospital, Tartu, Estonia. 4Center of Physical
Activity Research, Rigshospitalet and Copenhagen University, Copenhagen,
Denmark. 5Department of Respiratory Medicine & Allergology, Skåne
University Hospital, Lund, Sweden. 6Faculty of Medicine, University of Iceland,
Reykjavik, Iceland. 7Department of Respiratory Diseases, Montpellier
University Hospitals, Hopital Arnaud de Villeneuve and PhyMed Exp (INSERM
U 1046, CNRS UMR9214), Universite de Montpellier, Montpellier, France.
8Department of Respiratory Medicine, Ghent University Hospital, Ghent,
Belgium. 9Departments of Epidemiology and Respiratory Medicine, Erasmus
Medical Center Rotterdam, Rotterdam, The Netherlands. 10Optimum Patient
Care, Cambridge, UK. 11Centre for Public Health, Queen’s University Belfast,
Belfast, UK. 12Personalized Medicine Asthma & Allergy Clinic, Humanitas
University & Research Hospital, Milan, Italy. 13SANI-Severe Asthma Network
Italy, Milan, Italy. 14Division of Allergy, Department of Medicine, Asan Medical
Center, College of Medicine, University of Ulsan, Seoul, South Korea. 15Faculty
of Public Health, Medical University – Sofia, Sofia, Bulgaria. 16Son Espases
University Hospital-IdISBa-Ciberes, Mallorca, Spain. 17Clinical Research Centre,
Smurfit Building Beaumont Hospital and Department of Respiratory
Medicine, RCSI, Dublin, Ireland. 18Australasian Severe Asthma Network,
Priority Research Centre for Healthy Lungs, University of Newcastle,
Newcastle, Australia. 19Department of Respiratory and Sleep Medicine,
Hunter Medical Research Institute, John Hunter Hospital, New Lambton
Heights, Australia. 20Centre for Experimental Medicine, Queen’s University
Belfast, Belfast, UK. 21Alfred Health & Monash University, Melbourne, Australia.
22Department of Respiratory Medicine & Allergology, Faculty of Medicine,
Kindai University Hospital, Ōsakasayama, Japan. 23Guy’s & St Thomas’ NHS
Trust and King’s College London, London, UK. 24Faculty of Medicine &
Dentistry, University of Plymouth, Plymouth, UK. 25Department of Respiratory
& Critical Care Medicine, Singapore General Hospital and Duke-National
University Singapore Medical School, Singapore, Singapore. 26Allergy Centre,
Tampere University Hospital and Tampere University, Tampere, Finland.
27Department of Respiratory Medicine, Faculty of Medicine, Landspitali
University Hospital and University of Iceland, Reykjavik, Iceland. 28University
of Amsterdam, Amsterdam, The Netherlands. 29Royal Brompton & Harefield
NHS Foundation Trust, London, UK. 30University of Athens, Athens, Greece.
31University of Manchester, Manchester, UK. 32Pneumology Service, Hospital
Universitario Lucus Augusti, Lugo, Spain. 33University of Sydney Medical
School, Sydney, Australia. 34UK Severe Asthma Network, Barts Health NHS
Trust and Queen Mary University of London, London, UK. 35University
Hospital “Sv. Ivan Rilski”, Sofia, Bulgaria. 36Bispebjerg Hospital, Copenhagen
University, Copenhagen, Denmark. 37The Catholic University of Korea, Seoul,
South Korea. 38Faculty of Pharmaceutical Sciences, University of British
Columbia, Vancouver, Canada. 39Division of Allergy & Clinical Immunology,
Department of Medicine, National Jewish Health and Division of Allergy &
Clinical Immunology, Department of Internal Medicine, University of
Colorado Hospital, Denver and Aurora, CO, USA. 40Division of Pulmonary,
Critical Care and Sleep Medicine, Asthma Program, National Jewish Health,
Denver, USA. 41Observational and Pragmatic Research Institute, Singapore,
FitzGerald et al. BMC Medical Research Methodology          (2020) 20:212 Page 13 of 14
Singapore. 42Academic Primary Care, Division of Applied Health Sciences,
University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen AB25 2ZD,
UK.
Received: 11 December 2019 Accepted: 26 June 2020
References
1. Lefaudeux D, De Meulder B, Loza MJ, Peffer N, Rowe A, Baribaud F, et al. U-
BIOPRED clinical adult asthma clusters linked to a subset of sputum omics. J
Allergy Clin Immunol. 2017;139:1797–807.
2. Moore WC, Hastie AT, Li X, Li H, Busse WW, Jarjour NN, et al. Sputum
neutrophil counts are associated with more severe asthma phenotypes
using cluster analysis. J Allergy Clin Immunol. 2014;133:1557–63 e5.
3. Moore WC, Meyers DA, Wenzel SE, Teague WG, Li H, Li X, et al. Identification
of asthma phenotypes using cluster analysis in the severe asthma research
program. Am J Respir Crit Care Med. 2010;181:315–23.
4. Pavord ID, Beasley R, Agusti A, Anderson GP, Bel E, Brusselle G, et al. After
asthma: redefining airways diseases. Lancet. 2018;391:350–400.
5. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al.
International ERS/ATS guidelines on definition, evaluation and treatment of
severe asthma. Eur Respir J. 2014;43:343–73.
6. Hekking P-PW, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH.
The prevalence of severe refractory asthma. J Allergy Clin Immunol. 2015;
135:896–902.
7. von Bülow A, Backer V, Bodtger U, Søes-Petersen NU, Vest S, Steffensen I,
et al. Differentiation of adult severe asthma from difficult-to-treat asthma –
outcomes of a systematic assessment protocol. Respir Med. 2018;145:41–7.
8. Chipps BE, Haselkorn T, Paknis B, Ortiz B, Bleecker ER, Kianifard F, et al. More
than a decade follow-up in patients with severe or difficult-to-treat asthma:
The Epidemiology and Natural History of Asthma: Outcomes and Treatment
Regimens (TENOR) II. J Allergy Clin Immunol. 2018;141:1590–7 e9.
9. Dean BB, Calimlim BC, Sacco P, Aguilar D, Maykut R, Tinkelman D.
Uncontrolled asthma: assessing quality of life and productivity of children
and their caregivers using a cross-sectional internet-based survey. Health
Qual Life Outcomes. 2010;8:96.
10. Chastek B, Korrer S, Nagar SP, Albers F, Yancey S, Ortega H, et al. Economic
burden of illness among patients with severe asthma in a managed care
setting. J Manag Care Spec Pharm. 2016;22:848–61.
11. Sadatsafavi M, Lynd L, Marra C, Carleton B, Tan WC, Sullivan S, et al. Direct
health care costs associated with asthma in British Columbia. Can Respir J.
2010;17:74–80.
12. Zeiger RS, Schatz M, Dalal AA, Qian L, Chen W, Ngor EW, et al. Utilization
and costs of severe uncontrolled asthma in a managed-care setting. J
Allergy Clin Immunol Pract. 2016;4:120–9 e3.
13. Heaney LG, Brightling CE, Menzies-Gow A, Stevenson M, Niven RM, British
Thoracic Society difficult asthma network. Refractory asthma in the UK: cross-
sectional findings from a UK multicentre registry. Thorax. 2010;65:787–94.
14. Schleich F, Brusselle G, Louis R, Vandenplas O, Michils A, Pilette C, et al.
Heterogeneity of phenotypes in severe asthmatics. The Belgian severe
asthma registry (BSAR). Respir Med. 2014;108:1723–32.
15. Korn S, Hübner M, Hamelmann E, Buhl R. The German severe asthma
registry. Pneumologie (Stuttgart, Germany). 2012;66:341–4.
16. Heffler E, Blasi F, Latorre M, Menzella F, Paggiaro P, Pelaia G, et al. The
severe asthma network in Italy: findings and perspectives. J Allergy Clin
Immunol Pract. 2019;7:1462–8.
17. Vennera MDC, Pérez De Llano L, Bardagí S, Ausin P, Sanjuas C, González H,
et al. Omalizumab therapy in severe asthma: experience from the Spanish
registry—some new approaches. J Asthma. 2012;49:416–22.
18. Bousquet J, Mantzouranis E, Cruz AA, Aït-Khaled N, Baena-Cagnani CE,
Bleecker ER, et al. Uniform definition of asthma severity, control, and
exacerbations: document presented for the World Health Organization
consultation on severe asthma. J Allergy Clin Immunol. 2010;126:926–38.
19. Global Initiative for Asthma. Global Strategy for Asthma Management and
Prevention, 2018. https://www.ginasthma.org. Accessed 13 November 2019.
20. Zervas E, Samitas K, Papaioannou AI, Bakakos P, Loukides S, Gaga M. An
algorithmic approach for the treatment of severe uncontrolled asthma. ERJ
Open Res. 2018;4:00125–2017.
21. Agache I, Ryan D, Rodriguez MR, Yusuf O, Angier E, Jutel M. Allergy
management in primary care across European countries – actual status.
Allergy. 2013;68:836–43.
22. Peters DH, Garg A, Bloom G, Walker DG, Brieger WR, Hafizur RM. Poverty
and access to health care in developing countries. Ann N Y Acad Sci. 2008;
1136:161–71.
23. European Network of Centres for Pharmacoepidemiology and
Pharmacovigilance (ENCePP®). http://www.encepp.eu/encepp/viewResource.
htm?id=24389. Accessed 13 November 2019.
24. Optimum Patient Care. The Optimum Patient Care Research Database
(OPCRD). http://optimumpatientcare.org/database-overview/. Accessed 13
November 2019.
25. Respiratory effectiveness group (REG). http://effectivenessevaluation.org/.
Accessed 13 November 2019.
26. Respiratory effectiveness group. ADEPT Committee. http://
effectivenessevaluation.org/adept-committee/. Accessed 13 November 2019.
27. National Asthma Education and Prevention Program, National Heart, Lung
and Blood Institute. Expert Panel Report 3: Guidelines for the Diagnosis &
Management of Asthma. 2007. http://www.ncbi.nlm.nih.gov/books/
NBK7232/. Accessed 13 November 2019.
28. European Commission. 2018 reform of EU data protection rules. 2018.
https://ec.europa.eu/commission/priorities/justice-and-fundamental-rights/
data-protection/2018-reform-eu-data-protection-rules_en . Accessed 13 Nov
2019.
29. SNOMED CT United States Edition. 2019. https://www.nlm.nih.gov/healthit/
snomedct/us_edition.html. Accessed 13 Nov 2019.
30. Okoli C, Pawlowski SD. The Delphi method as a research tool: an example,
design considerations and applications. Inf Manag. 2004;42:15–29.
31. Bulathsinhala L, Eleangovan N, Heaney LG, Menzies-Gow A, Gibson PG,
Peters M, et al. Development of the International Severe Asthma Registry
(ISAR): a modified Delphi study. J Allergy Clin Immunol Pract. 2019;7:578–88
e2.
32. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, et al.
Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J
Med. 2009;360:973–84.
33. Roufosse FE, Kahn J-E, Gleich GJ, Schwartz LB, Singh AD, Rosenwasser LJ,
et al. Long-term safety of mepolizumab for the treatment of
hypereosinophilic syndromes. J Allergy Clin Immunol. 2013;131:461–7 e5.
34. Wang E, Wechsler ME, Tran TN, Heaney LG, Jones RC, Menzies-Gow AN,
et al. Characterization of severe asthma worldwide: data from the
International Severe Asthma Registry. Chest. 2020;157:790–804.
35. Carr TF, Zeki AA, Kraft M. Eosinophilic and noneosinophilic asthma. Am J
Resp Crit Care Med. 2018;197:22–37.
36. Bladen CL, Rafferty K, Straub V, Monges S, Moresco A, Dawkins H, et al. The
TREAT-NMD Duchenne muscular dystrophy registries: conception, design,
and utilization by industry and academia. Hum Mutat. 2013;34:1449–57.
37. Pugliatti M, Eskic D, Mikolcić T, Pitschnau-Michel D, Myhr KM, Sastre-Garriga
J, et al. Assess, compare and enhance the status of persons with multiple
sclerosis (MS) in Europe: a European register for MS. Acta Neurol Scand.
2012;126:24–30.
38. Michaud K, Berglind N, Franzén S, Frisell T, Garwood C, Greenberg JD, et al.
Can rheumatoid arthritis (RA) registries provide contextual safety data for
modern RA clinical trials? The case for mortality and cardiovascular disease.
Ann Rheum Dis. 2016;75:1797.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
FitzGerald et al. BMC Medical Research Methodology          (2020) 20:212 Page 14 of 14
